Co-Diagnostics Submits FDA 510(k) for PCR Respiratory Test
Salt Lake City, Utah, USA, August 7, 2026 Co-Diagnostics, Inc. has reached a major regulatory milestone by submitting a...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Salt Lake City, Utah, USA, August 7, 2026 Co-Diagnostics, Inc. has reached a major regulatory milestone by submitting a...
SALT LAKE CITY, July 22, 2026 Co-Diagnostics, Inc. has announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd.,...
SALT LAKE CITY, Utah, July 1, 2026 Co-Diagnostics, Inc. has reached a significant regulatory milestone by completing the clinical...
